Real-world safety of difelikefalin for chronic kidney disease–associated pruritus: initial insights from a European managed access programme
No new safety signals were detected in this MAP analysis over a 3-year period. The overall safety results were consistent with the known safety profile for difelikefalin patients with moderate-to-severe CKD-aP receiving HD.
Authors
- Marius Constantin Manu (ORCID: https://orcid.org/0000-0003-1526-3375)
- Joerg Latus (ORCID: https://orcid.org/0000-0003-0584-4870)
- Lucio Manenti (ORCID: https://orcid.org/0000-0002-4144-2142)
- Carlos Narváez (ORCID: https://orcid.org/0009-0007-5932-9547)
- Gert Mayer (ORCID: https://orcid.org/0000-0002-5039-543X)
- Despina Ruessmann
- S Candoso Neri de Jesus
Institutions
- Innsbruck Medical University (AT)
- Robert Bosch Hospital (DE)
- ASL Roma (IT)
- Vifor Pharma (Switzerland) (CH)
- Azienda Unita' Sanitaria Locale di Parma (IT)
- Ospedale di Parma (IT)
- Hospital Universitario Puerta del Mar (ES)
- Vifor Pharma (United States) (US)
Publication Details
- Journal
- Clinical Kidney Journal
- Published
- 2025-09-23
- DOI
- https://doi.org/10.1093/ckj/sfaf297
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Fresenius Medical Care North America